Darusentan
From Self-sufficiency
| File:Darusentan.png | |
| Systematic (IUPAC) name | |
|---|---|
|
(2S)-2-(4,6-Dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid | |
| Clinical data | |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Biological half-life | 12.5 hours |
| Identifiers | |
| CAS Number | 171714-84-4 |
| ATC code | none |
| PubChem | CID 177236 |
| Chemical data | |
| Formula | C22H22N2O6 |
| Molar mass | 410.42 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Darusentan (LU-135252; HMR-4005) is a endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences,[1] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.[2]
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." /> |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Pharmacology stubs
- Endothelin receptor antagonists
- Pyrimidines
- Phenol ethers
- 2Fix
